![]() |
市場調查報告書
商品編碼
1451627
2024-2032 年按細胞類型、治療類型、治療領域、最終用戶和地區分類的細胞治療市場報告Cell Therapy Market Report by Cell Type, Therapy Type, Therapeutic Area, End User, and Region 2024-2032 |
2023年全球細胞治療市場規模達135億美元。展望未來, IMARC Group預計到2032年市場規模將達到505億美元,2024-2032年複合年成長率(CAGR)為15.28%。幹細胞研究的不斷進步、全球醫療保健基礎設施的不斷完善、患者意識的提高、政府支持的不斷升級以及保險覆蓋範圍的擴大是推動市場發展的一些因素。
細胞療法(CT)涉及移植人體細胞以解決組織和細胞損傷,為各種醫療狀況提供解決方案。這種包羅萬象的方法融合了不同的細胞類型,包括造血幹細胞 (HSC)、骨骼肌和間質幹細胞、淋巴細胞、樹突狀細胞和胰島細胞。其應用範圍不僅限於增強免疫系統以治療癌症,還包括治療自體免疫疾病和傳染病、泌尿問題、關節軟骨損傷、脊髓損傷、免疫系統減弱和神經系統疾病。它在再生藥物的製造中發揮關鍵作用,能夠開發和實施旨在組織和器官修復以及受衰老、疾病或損傷影響的功能恢復的新型治療方法。
全球市場主要由生物技術的快速進步所推動。與此一致的是,不斷增加的研發活動對市場做出了重大貢獻。此外,政府和私人投資者不斷增加的資金推動了研究和商業化。除此之外,不斷擴大的臨床試驗活動驗證了細胞療法的有效性和安全性,刺激了市場。此外,慢性病和退化性疾病發生率的不斷上升需要先進的治療方案,從而推動了市場的發展。人口老化需要針對與年齡相關的疾病的再生療法,從而提振了市場。此外,針對個別患者的個人化細胞療法正在受到關注,促進了市場成長。監管機構為細胞療法的核准提供了更清晰的途徑,為市場創造了積極的前景。競爭推動細胞治療產品的創新與多樣化。此外,罕見疾病盛行率的不斷上升也推動了市場的發展。
各種疾病的盛行率不斷增加,例如癌症和心臟異常
各種疾病的日益流行,特別是癌症和心臟異常,對市場產生了有利的影響。由於人口老化、生活方式的改變和環境影響等因素,這些疾病的全球負擔穩定上升。細胞療法利用特殊細胞的再生和修復特性,在治療和治癒這些疾病方面具有巨大的前景。對於癌症,基於細胞的免疫療法,例如 CAR-T 細胞療法,在靶向和消除癌細胞方面已取得了顯著的成功。在心臟異常的情況下,基於幹細胞的療法旨在修復受損的心臟組織並改善心臟功能。對這些廣泛傳播且危及生命的疾病的有效治療的迫切需要推動了對細胞治療方法的廣泛研究、開發和投資。
細胞療法的臨床研究數量不斷增加
細胞療法的臨床研究數量不斷增加正在推動市場成長。臨床試驗在驗證這些創新療法的安全性和有效性方面發揮基礎作用。隨著臨床研究的發展,對解決癌症、自體免疫疾病和退化性疾病等各種疾病的新療法的需求不斷成長。製藥公司、學術機構和生技公司正在積極進行這些試驗,將細胞療法推向市場。這些研究產生的大量資料證明了細胞療法的治療潛力,同時也有助於完善治療方案和確定最合適的患者群體。此外,美國FDA等監管機構積極支持並加速細胞療法的核准流程,進一步激勵臨床試驗的啟動。因此,越來越多的臨床研究促進了細胞療法的進步,促進了創新並擴大了對有需要的患者的可近性。這一因素強調了臨床研究在推動市場方面所扮演的重要角色。
在全球拓展醫療保健產業
全球不斷擴張的醫療保健產業為市場提供了許多機會。隨著人口成長、老化以及慢性病負擔的增加,對先進醫療的需求顯著增加。醫療保健產業的擴張包括開發細胞療法等尖端療法。全球的醫療保健系統正在認知到細胞療法在解決從癌症和心血管疾病到神經系統疾病和自體免疫疾病等多種醫療狀況的潛力。這種認可轉化為再生醫學和細胞療法領域投資、研究和臨床試驗的增加。此外,隨著新興經濟體醫療基礎設施的改善,包括細胞療法在內的先進醫療方法變得更加容易取得。醫療保健服務的全球擴張擴大了細胞治療的潛在患者群體,推動了市場成長。
The global cell therapy market size reached US$ 13.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 50.5 Billion by 2032, exhibiting a growth rate (CAGR) of 15.28% during 2024-2032. The increasing advances in stem cell research, the rising healthcare infrastructure across the globe, the growing patient awareness, the escalating government support, and the expanding insurance coverage are some of the factors propelling the market.
Cell therapy (CT) involves the transplantation of human cells to address tissue and cell damage, providing solutions for various medical conditions. This encompassing approach incorporates different cell types, including hematopoietic stem cells (HSC), skeletal muscle and mesenchymal stem cells, lymphocytes, dendritic cells, and pancreatic islet cells. Its applications extend beyond immune system enhancement for cancer treatment to encompass the management of autoimmune and infectious diseases, urinary issues, joint cartilage damage, spinal cord injuries, weakened immune systems, and neurological disorders. It plays a pivotal role in manufacturing regenerative medicines, enabling the development and implementation of novel treatments aimed at tissue and organ restoration and the recovery of functions impacted by aging, diseases, or injuries.
The global market is majorly driven by the rapid advancements in biotechnology. In line with this, the increasing research and development activities are significantly contributing to the market. Furthermore, the rising funding from governments and private investors fuels research and commercialization. Apart from this, the expanding clinical trial activities validate the efficacy and safety of cell therapies, catalyzing the market. Moreover, the growing incidence of chronic and degenerative diseases necessitates advanced treatment options, propelling the market. An aging demographic requires regenerative therapies for age-related conditions, bolstering the market. Besides, personalized cell therapies tailored to individual patients are gaining traction, fostering market growth. Regulatory bodies provide clearer pathways for cell therapy approvals, creating a positive outlook for the market. Competition drives innovation and diversification of cell therapy products. Additionally, the escalating prevalence of rare diseases is providing a boost to the market.
Increasing prevalence of various diseases, such as cancer and cardiac abnormalities
The increasing prevalence of various diseases, particularly cancer and cardiac abnormalities, is favorably impacting the market. The global burden of these diseases has steadily risen due to factors like aging populations, lifestyle changes, and environmental influences. Cell therapy holds immense promise in treating and potentially curing these conditions by utilizing specialized cells' regenerative and reparative properties. For cancer, cell-based immunotherapies, such as CAR-T cell therapy, have shown remarkable success in targeting and eliminating cancer cells. In the case of cardiac abnormalities, stem cell-based therapies aim to repair damaged heart tissue and improve cardiac function. The urgent need for effective treatments for these widespread and life-threatening diseases propels extensive research, development, and investment in cell therapy approaches.
Rising number of clinical studies for cell-based therapies
The rising number of clinical studies for cell-based therapies is fueling the market growth. Clinical trials play a fundamental role in validating the safety and efficacy of these innovative treatments. As clinical studies grow, the demand for novel therapies to address various medical conditions such as cancer, autoimmune diseases, and degenerative disorders grows. Pharmaceutical companies, academic institutions, and biotechnology firms are actively conducting these trials to bring cell-based therapies to the market. The wealth of data generated from these studies demonstrates the therapeutic potential of cell therapies but also aids in refining treatment protocols and identifying the most suitable patient populations. Moreover, regulatory agencies like the FDA in the United States actively support and expedite the approval process for cell-based therapies, further incentivizing the initiation of clinical trials. As a result, the increasing number of clinical studies catalyzes advancing cell therapies, fostering innovation and expanding their accessibility to needy patients. This factor underscores the significant role clinical research plays in propelling the market.
Expanding healthcare industry worldwide
The expanding healthcare industry worldwide is offering numerous opportunities for the market. As populations grow, age, and face an increasing burden of chronic diseases, the demand for advanced medical treatments rises significantly. The healthcare sector's expansion includes the development of cutting-edge therapies like cell-based treatments. Healthcare systems across the globe are recognizing the potential of cell therapy in addressing a wide range of medical conditions, from cancer and cardiovascular diseases to neurological disorders and autoimmune conditions. This recognition translates into increased investment, research, and clinical trials in regenerative medicine and cell therapy. Moreover, as healthcare infrastructure improves in emerging economies, there is greater accessibility to advanced medical treatments, including cell therapies. This global expansion of healthcare services broadens the potential patient pool for cell-based treatments, driving market growth.
IMARC Group provides an analysis of the key trends in each segment of the global cell therapy market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on cell type, therapy type, therapeutic area, and end user.
Stem Cell
Bone Marrow
Blood
Umbilical Cord-Derived
Adipose-Derived Stem Cell
Others
Non-stem Cell
Stem cell dominates the market
The report has provided a detailed breakup and analysis of the market based on the cell type. This includes stem cell (bone marrow, blood, umbilical cord-derived, adipose-derived stem cell, and others) and non-stem cell. According to the report, stem cell represented the largest segment.
Stem cells, with their remarkable regenerative potential and ability to differentiate into various cell types, have garnered significant attention in the medical field. These versatile cells are instrumental in treating a wide spectrum of diseases, including degenerative disorders, neurological conditions, and hematological malignancies. The increasing prevalence of age-related diseases and chronic conditions has intensified the demand for effective stem cell-based treatments. Moreover, ongoing research and clinical trials continue to unveil new therapeutic possibilities for stem cells, further fueling market growth. Pharmaceutical and biotechnology firms heavily invest in stem cell research, focusing on developing innovative therapies.
Furthermore, regulatory agencies are recognizing the importance of stem cell therapies, streamlining approval processes, and safety standards. This facilitates the commercialization of stem cell-based treatments, making them more accessible to patients worldwide. The stem cell segment is a powerful driver of growth in the cell therapy market, promising revolutionary solutions for numerous medical challenges.
Autologous
Allogeneic
Autologous dominates the market
The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes autologous and allogeneic. According to the report, autologous represented the largest segment.
Autologous therapies involve the extraction, manipulation, and reinfusion of a patient's cells, minimizing the risk of rejection and adverse reactions. This personalized approach has gained prominence in treating various conditions, including cancer, autoimmune diseases, and degenerative disorders. The increasing demand for therapies with higher safety profiles and reduced immune complications has fueled the adoption of autologous cell therapies. These treatments harness the regenerative potential of a patient's cells, addressing unmet medical needs while minimizing the risks associated with allogeneic treatments, where cells are sourced from donors.
Furthermore, advancements in cell processing techniques, such as CAR-T cell therapies for cancer treatment, showcase the remarkable potential of autologous therapies. Regulatory agencies are also streamlining approval pathways for these personalized treatments, expediting their availability to a wider patient population. As a result, the autologous therapy segment is a pivotal driver of growth in the cell therapy market, offering innovative and patient-centric solutions for various medical conditions.
Malignancies
Musculoskeletal Disorders
Autoimmune Disorders
Dermatology
Others
Malignancies dominate the market
The report has provided a detailed breakup and analysis of the market based on the therapeutic area. This includes malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. According to the report, malignancies represented the largest segment.
Malignancies, including various types of cancer, present one of the most challenging healthcare concerns globally. Cell therapies, such as CAR-T, have emerged as groundbreaking treatments for these conditions. The growing incidence of cancer and the increasing demand for more effective and targeted therapies have propelled the development and adoption of cell-based treatments. These therapies harness the patient's immune system or engineered cells to target and eliminate cancer cells. Their remarkable success in clinical trials and real-world applications underscores their potential to transform cancer treatment.
Moreover, regulatory agencies are expediting approvals for cell therapies in oncology, streamlining their path to market. As a result, the malignancies-focused segment serves as a critical driver of growth in the cell therapy market, offering renewed hope to cancer patients and contributing to the evolution of cancer care.
Hospitals and Clinics
Academic and Research Institutes
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, academic and research institutes.
Hospitals and clinics, with their advanced medical infrastructure and access to a broad patient base, are well-positioned to integrate cell therapy into their treatment protocols. They offer a range of cell-based treatments, including CAR-T cell therapy for cancer and stem cell therapies for various conditions, providing patients with advanced and personalized care options.
Furthermore, the collaboration between hospitals, clinics, and cell therapy companies fosters the expansion of clinical trials and the development of new therapies. As these healthcare facilities continue to recognize the potential of cell therapies in improving patient outcomes, their adoption and utilization of cell-based treatments contribute significantly to the market's overall growth.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America boasts a robust and highly developed healthcare infrastructure, including advanced research institutions, hospitals, and clinical centers. These institutions actively engage in cell therapy research and clinical trials, accelerating the development and adoption of innovative cell-based treatments. The substantial investments in the biotechnology and pharmaceutical sectors facilitate the advancement of cell therapies. Pharmaceutical companies and biotech firms in the region actively contribute to cell therapy research and development, resulting in a steady stream of new therapies.
The regulatory agencies in North America, such as the FDA in the United States, play a crucial role in streamlining the approval process for cell therapies, ensuring they meet rigorous safety and efficacy standards. This regulatory support expedites the commercialization of these treatments. Moreover, the increasing prevalence of chronic diseases, including cancer, fuels the demand for effective and advanced therapies, making cell therapies an attractive option for patients and healthcare providers.
Top companies are strengthening the market through multifaceted strategies and contributions. These industry leaders prioritize extensive research and development, continuously pushing the boundaries of cell therapies by exploring novel cell types, delivery methods, and applications. They conduct rigorous clinical trials, substantiating the safety and efficacy of their therapies and obtaining regulatory approvals that enhance market credibility. Strategic collaborations and partnerships with research institutions, biotech firms, and healthcare organizations allow them to leverage combined expertise and resources. Top companies often expand their market reach globally, making cell therapies accessible to a broader patient base. Maintaining strict compliance with regulatory standards ensures that their therapies meet stringent safety and quality requirements, instilling confidence among healthcare professionals and patients. Additionally, initiatives to improve patient access, educational campaigns, and strategic acquisitions collectively reinforce their pivotal role in advancing cell therapies and fostering market growth.
The report has provided a comprehensive analysis of the competitive landscape in the cell therapy market. Detailed profiles of all major companies have also been provided.
AlloSource
Anterogen Co. Ltd.
Cells for Cells
Holostem Terapie Avanzate S.r.l.
JCR Pharmaceuticals
Kolon TissueGene Inc
MEDIPOST
Mesoblast Limited
NuVasive
Stemedica Cell Technologies Inc.
Stempeutics Research Pvt. Ltd
Vericel Corporation
In July 2023, AlloSource received FDA 510(K) clearance for AceConnex pre-sutured fascia for hip labral eeconstruction and augmentation.
In June 2020, Holostem Terapie Avanzate S.r.l signed a contract for the transfer of the business branch of Holoclar, an autologous stem-cell therapy for the treatment of patients with severe ocular surface burns, with Chiesi Farmaceutici, international research-focussed group (Chiesi Group).
In October 2022, MEDIPOST announced the launch of a Contract Development and Manufacturing Organization (CDMO) business for cell and gene therapy products in Korea.